SynthesisFrontiers in neuroscience2026
Long-term neurodevelopment in preterm neonates with necrotizing enterocolitis: systematic review and meta-analysis.
Synthesis in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Necrotizing enterocolitis (NEC) is a common complication in preterm infants and is associated with significant mortality and long-term morbidity, including gastrointestinal sequelae, brain injury, and developmental delays. This systematic review and meta-analysis examines long-term neurodevelopmental outcomes in infants born at less than 34 weeks' gestation who survive NEC and identifies specific developmental domains most vulnerable to neurodevelopmental impairment. Methods: The systematic review was performed according to the PRISMA guidelines. We systematically searched Pubmed (including MEDLINE), Embase and Web of Science for relevant articles. Studies were graded for quality using the GRADE system and bias was assessed using the ROBINS-E Risk of Bias tool. We performed gestational-age stratified subgroup analyses (22-28 weeks versus 29-34 weeks) and evaluated the risk of impairment in different neurodevelopmental domains. Results: Survivors of NEC are at increased risk of neurodevelopmental impairment (RR 1.42, 95% CI 1.32-1.53). Several neurodevelopmental domains are negatively impacted, such as motor skills (RR 2.08, 95% CI 1.86-2.32), cognition (RR 1.75, 95% CI 1.57-1.96), vision (RR 4.36, 95% CI 2.91-6.55), hearing (RR 4.09, 95% CI 2.91-5.77) and cerebral palsy (RR 2.48, 95% CI 2.15-2.86). The risk of epilepsy and behavioral problems does not differ between NEC survivors and age-matched controls. This increased risk of impairment after NEC persists after stratification for gestational age and extends into school-age. Conclusion: NEC Survivors face an elevated risk of neurodevelopmental impairment, irrespective of gestational age, with deficits spanning multiple developmental domains. These findings highlight the need for targeted, long-term follow-up to enable timely detection and individualized interventions for developmental delays throughout childhood. Systematic review registration: http://www.crd.york.ac.uk/PROSPERO, identifier CRD42022322564.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.